TriGemX Bio to Go Public Through TCGX SPAC Merger

07:43 AM EDT, 10/19/2026 (MT Newswires) -- TCGX Acquisition (TCGX), a special purpose acquisition company, and TriGemX Bio said Monday that they have signed a business combination agreement to take the biotech firm public. The combined company will be named TriGemX Bio and will trade on the Nasdaq stock market under the ticker symbol TGEM. The transaction is expected to generate approximately $246 million of gross proceeds, before transaction costs and assuming no redemptions by TCGX Acquisition's public shareholders. This includes approximately $86 million from TCGX Acquisition's trust account and $160 million from a private investment in public equity financing of common stock at $10 per share from a group of healthcare investors. The investors include TCGX, Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital, and Vianti Capital.